Modifications of HIV-1 DNA and provirus-infected cells during 24 months of intermittent highly active antiretroviral therapy

Journal of Acquired Immune Deficiency Syndromes

Volumn 48, Issue 1, 2008, Pages 68-71

  Palmisano, Lucia ^a   Giuliano, Marina ^a   Chiarotti, Flavia ^a   Zanchetta, Marisa ^b   Andreotti, Mauro ^a   Pirillo, Maria F ^a   Riva, Elisabetta ^c   Antonelli, Guido ^d   Rossi, Anita De ^b   Vella, Stefano ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b Department of Oncology and Surgical Sciences   (Italy)

^c UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Highly active antiretroviral therapy; HIV 1 DNA; Treatment interruptions

Indexed keywords

ANTIRETROVIRUS AGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS DNA;

ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DNA, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; PROVIRUSES;

EID: 42649136566     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31816de83a     Document Type: Article

References (11)

1. Davey RT, Shar N, Yodler C, et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci USA. 1999;96:15109-15114.
2. Garcia F, Plana M, Vidal C, et al. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy. AIDS. 1999;13:F79-F86.
3. Erikkson LE, Falk KI, Bratt GA, et al. HIV type 1 DNA development during long-term supervised therapy interruption. AIDS Res Hum Retroviruses. 2003;19:259-265.
4. Burton CT, Nelson MR, Hay P, et al. Immunological and virological consequences of patient-directed antiretroviral therapy interruption during chronic HIV-1 infection. Clin Exp Immunol. 2005;142:354-361.
5. Palmisano L, Giuliano M, Bucciardini R, et al. Determinants of virologic and immunologic outcome in chronically HIV-1 - infected subjects undergoing repeated treatment interruptions: the ISS-PART study. J Acquir Immune Defic Syndr. 2007;46:39-47.
6. Ometto L, De Forni D, Patiri F, et al. Immune reconstitution in HIV-1 infected children on antiretroviral therapy: role of thymic output and viral fitness. AIDS. 2002;16:839-849.
7. Dianzani F, Antonelli G, Riva E, et al. Plasma HIV-1 viremia and viral load in lymph nodes. Nat Med. 1996;8:832-833.
8. Reed LJ, Muench H. A simple method for estimating fifty percent endpoints. Am J Hyg. 1938;27:493-497.
9. Anton PA, Mitsuyasu RT, Deeks SG, et al. Multiple measures of HIV-1 burden in blood and tissue are correlated with each other but not with clinical parameters in aviremic subjects. AIDS. 2003;17:53-63.
10. Garrigue I, Pellegrin I, Hoen B, et al. Cell-associated HIV-1 DNA quantitation after highly active antiretroviral therapy-treated primary infection in patients with persistently undetectable plasma HIV-1RNA. AIDS. 2000;14:2851-2855.
11. Frost SD, Martinez-Picado J, Ruiz L, et al. Viral dynamics during structured treatment interruptions of chronic human immunodeficiency virus type 1 infection. J Virol. 2002;76:968-979.